新的补充和替代药物配方的有效性和安全性研究方法:斯里兰卡新冠肺炎期间的经验教训。

Q2 Medicine
Senaka Pilapitiya, Saroj Jayasinghe, Anjana Silva, Rajitha Wickremasinghe, Priyani Paranagama, Janaka De Silva, Sarath Lekamwasam, S A M Kularatne, Kamani Wanigasuriya, Swarna Kaluthota, Saranga Sumathipala, Chinthaka Rathnnasooriya, Sisira Siribaddana
{"title":"新的补充和替代药物配方的有效性和安全性研究方法:斯里兰卡新冠肺炎期间的经验教训。","authors":"Senaka Pilapitiya,&nbsp;Saroj Jayasinghe,&nbsp;Anjana Silva,&nbsp;Rajitha Wickremasinghe,&nbsp;Priyani Paranagama,&nbsp;Janaka De Silva,&nbsp;Sarath Lekamwasam,&nbsp;S A M Kularatne,&nbsp;Kamani Wanigasuriya,&nbsp;Swarna Kaluthota,&nbsp;Saranga Sumathipala,&nbsp;Chinthaka Rathnnasooriya,&nbsp;Sisira Siribaddana","doi":"10.4103/WHO-SEAJPH.WHO-SEAJPH_67_22","DOIUrl":null,"url":null,"abstract":"<p><p>COVID-19 affected Sri Lanka from early 2020, a time of considerable ignorance accompanied by wide media coverage of a devastating epidemic in Italy and Europe. Many were attracted to complementary and alternative medicine (CAM) or traditional medicine (TM) in this desperate situation. Several preparations were claimed to be effective against COVID-19 globally. Dammika Bandara Syrup© was one such preparation promoted for preventing and treating SARS-CoV-2 infection. It was based on bees' honey, pericarp and mace of Myristica fragrans (nutmeg), the seed of Foeniculum vulgare and fresh rhizome of Zingiber officinale, all believed to have anti-viral properties. Following an unpublished clinical study claiming efficacy, Dammika Bandara Syrup© gained wide media publicity and political patronage. The producer claimed of Goddess Kali revealing the formula added an anthropological, cultural, and religious complexity to the issue. The demand for the product increased rapidly as a debate raged both in public and in the parliament on utilizing such products in combating COVID-19. The Department of Ayurveda, which is statutorily responsible for regulating CAM/TM had to respond to the situation. The legislation to regulate such indigenous medicinal products was weak, and the crisis deepened as thousands converged to the production facility, defying mobility restrictions introduced to control COVID-19. This led to the Ministry of Health requesting academics to form a team and conduct a clinical trial to prove its efficacy. This paper outlines the process and issues faced during the regulatory approval for the trial in a polarized political environment. Some health professionals accused the researchers of bowing to political pressure and questioned the scientific justification for the trial. However, the team considered this as an opportunity to streamline a path for research into CAM/TM therapies in situations such as COVID-19. Several processes were identified and addressed, such as the provisional registration of CAM preparations, assessing the potential efficacy of a CAM product, confirmation of authenticity and safety, standardization and supervision of production respecting cultural identities, obtaining approval for human use, choice of comparators, and ethical issues. We believe the study has helped set standards and a benchmark for CAM and TM research in Sri Lanka.</p>","PeriodicalId":37393,"journal":{"name":"WHO South-East Asia journal of public health","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Approach to Study the Efficacy and Safety of New Complementary and Alternative Medicine Formulations: Lesson during COVID-19 from Sri Lanka.\",\"authors\":\"Senaka Pilapitiya,&nbsp;Saroj Jayasinghe,&nbsp;Anjana Silva,&nbsp;Rajitha Wickremasinghe,&nbsp;Priyani Paranagama,&nbsp;Janaka De Silva,&nbsp;Sarath Lekamwasam,&nbsp;S A M Kularatne,&nbsp;Kamani Wanigasuriya,&nbsp;Swarna Kaluthota,&nbsp;Saranga Sumathipala,&nbsp;Chinthaka Rathnnasooriya,&nbsp;Sisira Siribaddana\",\"doi\":\"10.4103/WHO-SEAJPH.WHO-SEAJPH_67_22\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>COVID-19 affected Sri Lanka from early 2020, a time of considerable ignorance accompanied by wide media coverage of a devastating epidemic in Italy and Europe. Many were attracted to complementary and alternative medicine (CAM) or traditional medicine (TM) in this desperate situation. Several preparations were claimed to be effective against COVID-19 globally. Dammika Bandara Syrup© was one such preparation promoted for preventing and treating SARS-CoV-2 infection. It was based on bees' honey, pericarp and mace of Myristica fragrans (nutmeg), the seed of Foeniculum vulgare and fresh rhizome of Zingiber officinale, all believed to have anti-viral properties. Following an unpublished clinical study claiming efficacy, Dammika Bandara Syrup© gained wide media publicity and political patronage. The producer claimed of Goddess Kali revealing the formula added an anthropological, cultural, and religious complexity to the issue. The demand for the product increased rapidly as a debate raged both in public and in the parliament on utilizing such products in combating COVID-19. The Department of Ayurveda, which is statutorily responsible for regulating CAM/TM had to respond to the situation. The legislation to regulate such indigenous medicinal products was weak, and the crisis deepened as thousands converged to the production facility, defying mobility restrictions introduced to control COVID-19. This led to the Ministry of Health requesting academics to form a team and conduct a clinical trial to prove its efficacy. This paper outlines the process and issues faced during the regulatory approval for the trial in a polarized political environment. Some health professionals accused the researchers of bowing to political pressure and questioned the scientific justification for the trial. However, the team considered this as an opportunity to streamline a path for research into CAM/TM therapies in situations such as COVID-19. Several processes were identified and addressed, such as the provisional registration of CAM preparations, assessing the potential efficacy of a CAM product, confirmation of authenticity and safety, standardization and supervision of production respecting cultural identities, obtaining approval for human use, choice of comparators, and ethical issues. We believe the study has helped set standards and a benchmark for CAM and TM research in Sri Lanka.</p>\",\"PeriodicalId\":37393,\"journal\":{\"name\":\"WHO South-East Asia journal of public health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"WHO South-East Asia journal of public health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/WHO-SEAJPH.WHO-SEAJPH_67_22\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"WHO South-East Asia journal of public health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/WHO-SEAJPH.WHO-SEAJPH_67_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

新冠肺炎从2020年初开始影响斯里兰卡,这是一个相当无知的时期,伴随着媒体对意大利和欧洲毁灭性疫情的广泛报道。在这种绝望的情况下,许多人被补充和替代医学(CAM)或传统医学(TM)所吸引。有几种制剂声称在全球范围内对新冠肺炎有效。Dammika Bandara糖浆是一种用于预防和治疗严重急性呼吸系统综合征冠状病毒2型感染的制剂。它是以蜜蜂的蜂蜜、肉豆蔻的果皮和肉豆蔻、茴香的种子和姜的新鲜根茎为基础的,所有这些都被认为具有抗病毒特性。在一项未发表的声称有效的临床研究之后,Dammika Bandara糖浆获得了广泛的媒体宣传和政治赞助。制片人声称卡利女神揭示了这个公式,这给这个问题增加了人类学、文化和宗教的复杂性。随着公众和议会就利用此类产品抗击新冠肺炎展开激烈辩论,对该产品的需求迅速增加。法律上负责监管CAM/TM的阿育吠陀部不得不对这种情况作出回应。监管此类本土医药产品的立法薄弱,数千人聚集在生产设施,无视为控制新冠肺炎而实施的流动限制,危机加剧。这导致卫生部要求学者组成一个团队并进行临床试验,以证明其疗效。本文概述了在两极分化的政治环境中,该审判的监管审批过程和面临的问题。一些卫生专业人士指责研究人员屈服于政治压力,并质疑试验的科学依据。然而,该团队认为这是一个在新冠肺炎等情况下简化CAM/TM疗法研究路径的机会。确定并解决了几个过程,如CAM制剂的临时注册、评估CAM产品的潜在功效、真实性和安全性的确认、尊重文化特性的生产标准化和监督、获得人类使用批准、比较器的选择以及伦理问题。我们相信,这项研究有助于为斯里兰卡的CAM和TM研究制定标准和基准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Approach to Study the Efficacy and Safety of New Complementary and Alternative Medicine Formulations: Lesson during COVID-19 from Sri Lanka.

COVID-19 affected Sri Lanka from early 2020, a time of considerable ignorance accompanied by wide media coverage of a devastating epidemic in Italy and Europe. Many were attracted to complementary and alternative medicine (CAM) or traditional medicine (TM) in this desperate situation. Several preparations were claimed to be effective against COVID-19 globally. Dammika Bandara Syrup© was one such preparation promoted for preventing and treating SARS-CoV-2 infection. It was based on bees' honey, pericarp and mace of Myristica fragrans (nutmeg), the seed of Foeniculum vulgare and fresh rhizome of Zingiber officinale, all believed to have anti-viral properties. Following an unpublished clinical study claiming efficacy, Dammika Bandara Syrup© gained wide media publicity and political patronage. The producer claimed of Goddess Kali revealing the formula added an anthropological, cultural, and religious complexity to the issue. The demand for the product increased rapidly as a debate raged both in public and in the parliament on utilizing such products in combating COVID-19. The Department of Ayurveda, which is statutorily responsible for regulating CAM/TM had to respond to the situation. The legislation to regulate such indigenous medicinal products was weak, and the crisis deepened as thousands converged to the production facility, defying mobility restrictions introduced to control COVID-19. This led to the Ministry of Health requesting academics to form a team and conduct a clinical trial to prove its efficacy. This paper outlines the process and issues faced during the regulatory approval for the trial in a polarized political environment. Some health professionals accused the researchers of bowing to political pressure and questioned the scientific justification for the trial. However, the team considered this as an opportunity to streamline a path for research into CAM/TM therapies in situations such as COVID-19. Several processes were identified and addressed, such as the provisional registration of CAM preparations, assessing the potential efficacy of a CAM product, confirmation of authenticity and safety, standardization and supervision of production respecting cultural identities, obtaining approval for human use, choice of comparators, and ethical issues. We believe the study has helped set standards and a benchmark for CAM and TM research in Sri Lanka.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.10
自引率
0.00%
发文量
25
期刊介绍: The journal will cover technical and clinical studies related to health, ethical and social issues in field of Public Health, Epidemiology, primary health care, epidemiology, health administration, health systems, health economics, health promotion, public health nutrition, communicable and non-communicable diseases, maternal and child health, occupational and environmental health, social and preventive medicine. Articles with clinical interest and implications will be given preference.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信